PMID- 37792313
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240418
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 37
IP  - 12
DP  - 2023 Dec
TI  - Role of ascorbic acid in cardiac allograft vasculopathy.
PG  - e15153
LID - 10.1111/ctr.15153 [doi]
AB  - PURPOSE OF THE REVIEW: Cardiac allograft vasculopathy (CAV) is a progressive 
      fibroproliferative disease which occurs after heart transplantation and is 
      associated with significant long-term morbidity and mortality. Currently 
      available strategies including statins, mammalian target of rapamycin (mTOR) 
      inhibitors, and revascularization, have limited overall effectiveness in treating 
      this pathology once the disease process is established. mTOR inhibitors, while 
      effective when used early in the disease process, are not well tolerated, and 
      hence not routinely used in post-transplant care. RECENT DATA: Recent work on 
      rodent models have given us a novel mechanistic understanding of effects of 
      ascorbic acid in preventing CAV. TET methyl cytosine dioxygenase2 (TET2) reduces 
      vascular smooth muscle cell (VSMC) apoptosis and intimal thickening. TET2 is 
      repressed by interferon gamma (IFNgamma) in the setting of CAV. Ascorbic acid has been 
      shown to promote TET2 activity and attenuate allograft vasculopathy in animal 
      models and CAV progression in a small clinical trial. SUMMARY: CAV remains a 
      challenging disease process and needs better preventative strategies. Ascorbic 
      acid improves endothelial dysfunction, reduces reactive oxygen species, and 
      prevents development of intimal hyperplasia by preventing smooth muscle cell 
      apoptosis and hyperproliferation. Further large-scale randomized control studies 
      of ascorbic acid are needed to establish the role in routine post-transplant 
      management.
CI  - (c) 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Chang, Alyssa
AU  - Chang A
AD  - Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
FAU - Martin, Kathleen A
AU  - Martin KA
AD  - Division of Cardiology, Department of Medicine, University of Michigan, Ann 
      Arbor, Michigan, USA.
FAU - Colvin, Monica
AU  - Colvin M
AD  - Division of Cardiology, Department of Medicine, Yale University, New Haven, 
      Connecticut, USA.
FAU - Bellumkonda, Lavanya
AU  - Bellumkonda L
AUID- ORCID: 0000-0002-9317-9067
AD  - Division of Cardiology, Department of Medicine, University of Michigan, Ann 
      Arbor, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231004
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Ascorbic Acid/therapeutic use
MH  - *Heart Diseases/etiology
MH  - *Vascular Diseases/drug therapy/etiology/prevention & control
MH  - Transplantation, Homologous
MH  - *Heart Transplantation/adverse effects
MH  - Allografts
MH  - Mammals
OTO - NOTNLM
OT  - heart (allograft) function/dysfunction
OT  - heart disease: immune/inflammatory
OT  - vasculopathy
EDAT- 2023/10/04 12:43
MHDA- 2023/12/17 09:46
CRDT- 2023/10/04 11:23
PHST- 2023/09/04 00:00 [revised]
PHST- 2023/06/08 00:00 [received]
PHST- 2023/09/22 00:00 [accepted]
PHST- 2023/12/17 09:46 [medline]
PHST- 2023/10/04 12:43 [pubmed]
PHST- 2023/10/04 11:23 [entrez]
AID - 10.1111/ctr.15153 [doi]
PST - ppublish
SO  - Clin Transplant. 2023 Dec;37(12):e15153. doi: 10.1111/ctr.15153. Epub 2023 Oct 4.